Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies (COTI) and Delmar Chemicals have entered into a research and development collaboration agreement to advance selected small molecules.
Subscribe to our email newsletter
The companies will discover, select, screen and synthesize compounds for targets that are of specific interest to major pharmaceutical companies.
As part of the agreement, COTI will utilise its proprietary Artificial Intelligence drug discovery platform, CHEMSAS(R) to discover and optimize new drug candidates designed to address commercial and therapeutic opportunities.
Delmar will work on the medicinal chemistry analysis of the chemical structures along with synthesis of the promising candidates.
The collaboration is expected to leverage technical capabilities and financial resources of the companies to develop patentable preclinical assets for outlicensing.
COTI president and chief executive officer Wayne Danter said, "This collaboration represents an opportunity to extend the intellectual property in COTI’s growing portfolio and assists in positioning CHEMSAS(R)’ as a potential drug discovery engine of choice in the biopharmaceutical and research community."
Delmar president and CEO Pierre Plante said Delmar has confidence in CHEMSAS(R) and is pleased to be collaborating with COTI on the project.
”Synthesizing the molecules identified by COTI provides us with a unique opportunity to demonstrate our expertise in medicinal chemistry," Plante added.